In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on Incyte (INCY). The company’s shares closed last Monday at $79.30.
According to TipRanks.com, Frahm is a 5-star analyst with an average return of 19.8% and a 52.6% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Adaptimmune Therapeutics, and Magenta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $91.40 average price target, which is a 15.7% upside from current levels. In a report issued on February 4, Oppenheimer also maintained a Buy rating on the stock with a $96.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $96.79 and a one-year low of $71.84. Currently, Incyte has an average volume of 1.43M.
Based on the recent corporate insider activity of 115 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.
